FDA Weighs Options After Teva Wins Risperdal Spat
Teva Pharmaceutical Industries Ltd. has won the exclusive right to sell its generic version of Johnson & Johnson's blockbuster drug Risperdal in the U.S. for six months beginning at the end...To view the full article, register now.
Already a subscriber? Click here to view full article